140 related articles for article (PubMed ID: 29074003)
1. Therapeutic revolution in the management of diabetic retinopathy.
Hurley B
Can J Ophthalmol; 2017 Nov; 52 Suppl 1():S1-S2. PubMed ID: 29074003
[No Abstract] [Full Text] [Related]
2. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy.
Gross JG; Glassman AR
JAMA Ophthalmol; 2016 Jan; 134(1):13-4. PubMed ID: 26583372
[No Abstract] [Full Text] [Related]
3. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.
Gross JG; Glassman AR; Klein MJ; Jampol LM; Ferris FL; Bressler NM; Beck RW
JAMA Ophthalmol; 2017 Jun; 135(6):672-673. PubMed ID: 28492921
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal bevacizumab versus panretinal photocoagulation for treatment-naïve proliferative and severe nonproliferative diabetic retinopathy.
Ernst BJ; García-Aguirre G; Oliver SC; Olson JL; Mandava N; Quiroz-Mercado H
Acta Ophthalmol; 2012 Nov; 90(7):e573-4. PubMed ID: 22405048
[No Abstract] [Full Text] [Related]
5. Therapeutic effect of intravitreal anti-VEGF drugs on retinal neovascularization in diabetic retinopathy.
Jiang G; Han X; Qiao K; Liu S
Minerva Med; 2024 Apr; 115(2):218-220. PubMed ID: 35838253
[No Abstract] [Full Text] [Related]
6. Cost Evaluation of Laser versus Intravitreal Aflibercept for Proliferative Diabetic Retinopathy.
Yannuzzi NA; Sridhar J; Chang JS; Lin J; Kuriyan AE; Smiddy WE
Ophthalmology; 2018 Jul; 125(7):1121-1122. PubMed ID: 29571831
[No Abstract] [Full Text] [Related]
7. Results of a Randomized Clinical Trial of Aflibercept vs Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Is It Time to Retire Your Laser?
Glassman AR
JAMA Ophthalmol; 2017 Jul; 135(7):685-686. PubMed ID: 28570733
[No Abstract] [Full Text] [Related]
8. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy.
Yamaji H; Shiraga F; Shiragami C; Nomoto H; Fujita T; Fukuda K
Arch Ophthalmol; 2011 Jan; 129(1):106-7. PubMed ID: 21220639
[No Abstract] [Full Text] [Related]
9. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).
Isaacs TW; Barry C
Clin Exp Ophthalmol; 2006 Nov; 34(8):802-3. PubMed ID: 17073910
[TBL] [Abstract][Full Text] [Related]
10. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
[No Abstract] [Full Text] [Related]
11. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
[TBL] [Abstract][Full Text] [Related]
12. Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation.
Schmidinger G; Maar N; Bolz M; Scholda C; Schmidt-Erfurth U
Acta Ophthalmol; 2011 Feb; 89(1):76-81. PubMed ID: 21272288
[TBL] [Abstract][Full Text] [Related]
13. Reduced vision in a diabetic patient due to incidental leukaemic retinopathy.
Tsiamita O; Siempis T; Varikkara M
Clin Exp Optom; 2019 Jan; 102(1):91-93. PubMed ID: 29989226
[No Abstract] [Full Text] [Related]
14. Transient regression of new vessels after anti-vascular endothelial growth factor monotherapy in proliferative diabetic retinopathy.
Venkatesh R; Anilkumar A; Mangla R; Sharief S; Chhablani J
Clin Exp Optom; 2024 Jul; 107(5):587-588. PubMed ID: 37078163
[No Abstract] [Full Text] [Related]
15. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
[TBL] [Abstract][Full Text] [Related]
16. The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.
Tremolada G; Del Turco C; Lattanzio R; Maestroni S; Maestroni A; Bandello F; Zerbini G
Exp Diabetes Res; 2012; 2012():728325. PubMed ID: 22566995
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy.
Mason JO; Nixon PA; White MF
Am J Ophthalmol; 2006 Oct; 142(4):685-8. PubMed ID: 17011869
[TBL] [Abstract][Full Text] [Related]
18. Novel method used for assessing the size of the neovascularization.
Garg P; Singh AP; Agarwal S; Natarajan S
Retina; 2010 Oct; 30(9):1556; author reply 1557. PubMed ID: 20924273
[No Abstract] [Full Text] [Related]
19. Retinal detachment after bevacizumab.
Arevalo JF; Sanchez JG; Saldarriaga L; Berrocal MH; Fromow-Guerra J; Morales-Canton V; Wu L; Maia M; Saravia MJ; Bareño J;
Ophthalmology; 2011 Nov; 118(11):2304.e3-7. PubMed ID: 22047908
[No Abstract] [Full Text] [Related]
20. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
